GlassScriptPhysician profile
Randy D Bingham
NPI 1083721518
$658.61
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $172 · 2023: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $138.77 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $76.79 | 2021-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $64.61 | 2021-2023 | Breztri |
| Novo Nordisk INC | $59.26 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $54.14 | 2023 | |
| Amgen INC. | $42.92 | 2021-2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.80 | 2021 | |
| Abbvie INC. | $42.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.88 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $22.23 | 2021 | |
| Dexcom, INC. | $17.85 | 2022 | |
| Pfizer INC. | $17.11 | 2021 | |
| Eisai INC. | $13.64 | 2021 | |
| Merck Sharp & Dohme LLC | $13.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Bingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.